ALFA Finder| Management target | Revenue 100.0% FY27 |
|---|
| Revenue growth | 22% YoY growth driven by Rajasthan and retail expansion. |
|---|---|
| Margins | EBITDA margin fell to 25% due to upfront project costs. |
| Demand visibility | Strong visibility via long-term PPP contracts and retail network growth. |
| Management confidence | Balanced confidence despite temporary margin pressure from new projects. |
Growth
Revenue grew 22% YoY; like-for-like projects grew 12%. Retail revenue surged 64%.
Outlook
Projected Rajasthan revenue of ₹150-170Cr; retail expected to reach 10-15% of total mix.
Risks
Margin compression from upfront Rajasthan costs; significant receivables delays in Karnataka and Himachal Pradesh.
Last quarter's promises, checked
Delivered
- Guided 200+ CT/MRI centers → delivered 190+ with 17 in pipeline (= BEAT)
- Guided 54 NABL labs → delivered 54 NABL labs (= BEAT)
- Guided virtually 0 bad debt → delivered 0 bad debt despite delays (= BEAT)
Partly delivered
- Guided Rajasthan revenue ₹250-300Cr → delivered guidance cut to ₹150-170Cr (= PARTIAL)
- Guided retail contribution double-digits → delivered 8% (= PARTIAL)
Missed
- Guided EBITDA margin 29-30% → delivered 25% (= MISS)
- Guided receivables to 100 days → delivered 139 days (= MISS)
Earnings Call Transcript filed with BSE, NSE: KRSNAA. Summary written with AI assistance from the document.
Krsnaa Diagnostics Ltd: key numbers
- Share price
- ₹508.50
- Market cap
- ₹1,650 Cr
- Revenue (annual)
- ₹772.8 Cr
- Net profit (annual)
- ₹101.4 Cr
- P/E (TTM)
- 16.8×Sector 54.5×
- Promoter holding
- 27.11%+0.00% QoQ
- FII holding
- 3.84%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Krsnaa Diagnostics Ltd
All →Krsnaa Diagnostics Other Announcement
Krsnaa Diagnostics informs exchanges that its RTA, KFin Technologies, will shift its corporate office effective December 1, 2026. The registered office and the company's own operations are unaffected.
Krsnaa Diagnostics Convertible Warrants
Krsnaa's auditor certified upfront consideration for 16.21 lakh promoter warrants at Rs.566 each, totalling Rs.91.75 Crore issue value. Certificate confirms upfront money came directly from allottees' accounts.
- Value
- ₹91.75 Cr
Krsnaa Diagnostics Bags New Order from Municipal Corporation of Delhi
Krsnaa Diagnostics secured a 15-year cash-based PPP project from the Municipal Corporation of Delhi. The contract involves establishing CT Scan and MRI facilities at three public hospitals.
- From
- Municipal Corporation of Delhi (MCD)
- Execution
- 15 years
- diagnostic facilities
- 3.0 project sites
Krsnaa Diagnostics Earnings Call Transcript: Key Takeaways
Krsnaa hit ₹500 Cr H1 revenue, but heavy Rajasthan ramp-up costs and government receivable delays (₹472 Cr) are squeezing margins and PAT.
- Call
- Guides 45% growth
Krsnaa Diagnostics Investor Presentation: Key Takeaways
Q2 FY27 revenue INR 2,710 Mn (+32% YoY) and PAT INR 246 Mn (+3%). EBITDA margin fell to 27% from 29% on Rajasthan fixed costs.
Krsnaa Diagnostics Results Update
Krsnaa Diagnostics reported record Q2 revenue of Rs 2,710 million, up 32% year on year. H1 PAT fell to Rs 411 million on Rajasthan project costs.